SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Oct. 28, 2015--
MyoKardia, Inc. (“MyoKardia”) today announced the pricing of its initial
public offering of 5,437,500 shares of common stock at a public offering
price of $10.00 per share, before underwriting discounts and
commissions. All of the common stock is being offered by MyoKardia. In
addition, MyoKardia has granted the underwriters a 30-day option to
purchase up to an additional 815,625 shares of common stock from the
company at the public offering price. The company's shares are expected
to begin trading on The NASDAQ Global Select Market on October 29, 2015
under the ticker symbol “MYOK.” The offering is expected to close on
November 3, 2015 subject to customary closing conditions.
Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting
as lead book-running managers. Wells Fargo Securities is acting as
book-running manager. Wedbush PacGrow is acting as co-manager.
A registration statement relating to the securities being sold in the
offering was declared effective by the Securities and Exchange
Commission on October 28, 2015. This offering is being made only by
means of a prospectus. When available, copies of the final prospectus
relating to this offering may be obtained by contacting: Credit Suisse
Securities (USA) LLC, Attention: Prospectus Department, One Madison
Avenue, New York, NY 10010, by telephone at (800) 221-1037, or by email
or Cowen and Company, LLC, c/o Broadridge Financial Services, Attention:
Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or
by telephone at (631) 274-2806 or by fax at (631) 254-7140.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
View source version on businesswire.com: http://www.businesswire.com/news/home/20151028006906/en/
Source: MyoKardia, Inc.
Pure Communications, Inc.
Matt Clawson, 949-370-8500